मर्कैप्टोप्यूरिन के इंटरैक्शन
हम जिन FDA लेबल और फैक्ट शीट को इंडेक्स करते हैं, उनमें मर्कैप्टोप्यूरिन (Purixan; एंटीमेटाबोलाइट) के 109 इंटरैक्शन दर्ज हैं: 13 गंभीर, 81 मध्यम, 14 मामूली, और 1 ऐसे जिनमें लेबल बताता है कि कोई महत्वपूर्ण इंटरैक्शन नहीं है। नीचे की हर प्रविष्टि उस वाक्य को उद्धृत करती है जिस पर वह आधारित है। दवा का यह पेज एक शुरुआती बिंदु है, आपकी स्थिति के लिए कोई फ़ैसला नहीं।
लेबल से लिए गए इंटरैक्शन
गंभीर इंटरैक्शन (13)
Immunosuppressants Everolimus Sirolimus Temsirolimus (IV) Not recommended during and 2 weeks after TOLSURA treatment. (इट्राकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)
Almost all had received azathioprine or 6- mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. (इन्फ्लिक्सिमैब लेबल, बॉक्स्ड चेतावनी)
Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. (एडालिमुमैब लेबल, बॉक्स्ड चेतावनी)
About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (कैप्टोप्रिल लेबल, चेतावनियां)
Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (क्लैड्रिबिन लेबल, दवाओं के इंटरैक्शन)
…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (टैक्रोलिमस लेबल, बॉक्स्ड चेतावनी)
ULORIC is contraindicated in patients being treated with azathioprine or mercaptopurine [see Drug Interactions (7) ] . (फेबुक्सोस्टैट लेबल, निषेध (कॉन्ट्राइंडिकेशन))
Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (फ्लुड्रोकॉर्टिसोन लेबल, चेतावनियां)
Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. (फ्लुनिसोलाइड लेबल, सावधानियां)
If concomitant use of APRISO and azathioprine or 6-mercaptopurine cannot be avoided, monitor blood tests, including complete blood cell counts and platelet counts. (मेसालामाइन लेबल, दवाओं के इंटरैक्शन)
In kidney, liver, and heart transplant patients Neoral may be administered with other immunosuppressive agents. (साइक्लोस्पोरिन लेबल, बॉक्स्ड चेतावनी)
मध्यम इंटरैक्शन (81)
Warfarin : Mercaptopurine tablets may decrease the anticoagulant effect. (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)
Warfarin : Mercaptopurine tablets may decrease the anticoagulant effect. (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
Warfarin : Mercaptopurine tablets may decrease the anticoagulant effect. (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
Warfarin : Mercaptopurine tablets may decrease the anticoagulant effect. (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
Immunosuppressants: Cyclosporine, tacrolimus, sirolimus and others metabolized by CYP3A ↓ immunosuppressant Dose adjustments of the immunosuppressant may be required. (एफाविरेंज़ लेबल, दवाओं के इंटरैक्शन)
Immunosuppressants: Cyclosporine, tacrolimus, sirolimus, and others metabolized by CYP3A ↓ immunosuppressant Dose adjustments of the immunosuppressant may be required. (एफाविरेंज़, लैमिवुडिन और टेनोफोविर लेबल, दवाओं के इंटरैक्शन)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (एम्लोडिपिन लेबल, दवाओं के इंटरैक्शन)
Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (एम्लोडिपिन और एटोरवास्टेटिन लेबल, दवाओं के इंटरैक्शन)
Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (एम्लोडिपिन और ओल्मेसार्टन लेबल, दवाओं के इंटरैक्शन)
Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when coadministered. (एम्लोडिपिन और वाल्सार्टन लेबल, दवाओं के इंटरैक्शन)
Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
Reduce the dose of mercaptopurine tablets when coadministered with allopurinol [see Dosage and Administration (2.4)] . (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
Immuno-suppressants: e.g., cyclosporine (CsA) sirolimus tacrolimus ↑ immuno-suppressants ↑ elvitegravir (with CsA) ↑ cobicistat (with CsA) Therapeutic monitoring of the immunosuppressive agents is recommended upon coadministration with GENVOYA. (एल्विटेग्राविर, कोबिसिस्टैट, एमट्रिसिटाबिन और टेनोफोविर लेबल, दवाओं के इंटरैक्शन)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (ओल्मेसार्टन, एम्लोडिपिन और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)
Immunosuppressants everolimus, rapamycin (also known as sirolimus), temsirolimus budesonide, ciclesonide, cyclosporine, dexamethasone, fluticasone, methylprednisolone, tacrolimus Rapamycin (sirolimus): Ketoconazole tablets 200 mg daily for 10 days increased the C max and AUC of a single 5 mg dose of sirolimus by 4.3 fold and 10.9 fold, respectively in 23 healthy… (कीटोकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
Cyclosporine, tacrolimus: Monitor for toxicities of these immunosuppressive drugs ( 7.1 ) (टिनिडाज़ोल लेबल, दवाओं के इंटरैक्शन)
- टेम्सिरोलिमसमध्यम
Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (टेल्मिसार्टन और एम्लोडिपिन लेबल, दवाओं के इंटरैक्शन)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
Enhanced myelosuppression has been noted in some patients also receiving trimethoprim-sulfamethoxazole. (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
- डेनोसुमैबमध्यम
Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (डेनोसुमैब लेबल, चेतावनियां और सावधानियां)
Warfarin : Mercaptopurine tablets may decrease the anticoagulant effect. (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
- डॉक्सोरूबिसिनमध्यम
Concomitant Use of 6-Mercaptopurine Doxorubicin hydrochloride may potentiate 6-mercaptopurine-induced hepatotoxicity. (डॉक्सोरूबिसिन लेबल, दवाओं के इंटरैक्शन)
Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
Immunosuppressive Agents There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with nefazodone. (नेफाज़ोडोन लेबल, दवाओं के इंटरैक्शन)
Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
- पेनिसिलामिनमध्यम
Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (पेनिसिलामिन लेबल, चेतावनियां)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route… (फेनोफाइब्रिक एसिड लेबल, दवाओं के इंटरैक्शन)
Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including fenofibrate, there is a risk that an interaction will lead to deterioration of renal… (फेनोफाइब्रेट लेबल, दवाओं के इंटरैक्शन)
Warfarin : Mercaptopurine tablets may decrease the anticoagulant effect. (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
Azathioprine or 6-Mercaptopurine: Increased risk of blood disorders; monitor complete blood cell counts and platelet counts. (बाल्सालाज़ाइड लेबल, दवाओं के इंटरैक्शन)
Warfarin : Mercaptopurine tablets may decrease the anticoagulant effect. (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
- बेंडामुस्टिनमध्यम
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (बेंडामुस्टिन लेबल, चेतावनियां और सावधानियां)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
…Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine… (रिफापेंटिन लेबल, दवाओं के इंटरैक्शन)
Glipizide Decrease exposure Immunosuppressive Agents Cyclosporine Decrease exposure Tacrolimus Prevention or Management: Monitoring of whole blood concentrations and appropriate dosage adjustments of tacrolimus are recommended when rifampin and tacrolimus are used concomitantly. (रिफैम्पिसिन लेबल, दवाओं के इंटरैक्शन)
Warfarin : Mercaptopurine tablets may decrease the anticoagulant effect. (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
HBV reactivation has also been reported in patients receiving certain immunosuppressants or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (लेडिपासविर और सोफोसबुविर लेबल, चेतावनियां और सावधानियां)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
Monitor the international normalized ratio (INR) in patients receiving warfarin and adjust the warfarin dosage as appropriate. (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
Enhanced myelosuppression has been noted in some patients also receiving trimethoprim-sulfamethoxazole. (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
Aminosalicylates Aminosalicylates (e.g., mesalamine, olsalazine or sulfasalazine) may inhibit the TPMT enzyme, which may increase the risk of myelosuppression when coadministered with mercaptopurine tablets. (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)
HBV reactivation has also been reported in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (सोफोसबुविर और वेल्पाटासविर लेबल, चेतावनियां और सावधानियां)
Warfarin : Mercaptopurine tablets may decrease the anticoagulant effect. (मर्कैप्टोप्यूरिन लेबल, दवाओं के इंटरैक्शन)
मामूली ज़िक्र (14)
- एक्सिटिनिबमामूली
Thirty-four patients were treated with corticosteroids and one patient was treated with a non-steroidal immunosuppressant. (एक्सिटिनिब लेबल, चेतावनियां और सावधानियां)
IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (एज़ेटिमाइब और सिमवास्टेटिन लेबल, चेतावनियां और सावधानियां)
IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persists despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (एटोरवास्टेटिन लेबल, चेतावनियां और सावधानियां)
Immunosuppressive Drugs Tacrolimus: Tacrolimus has been shown to be metabolized via the CYP3A system. (निफेडिपिन लेबल, सावधानियां)
IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (पिटावास्टेटिन लेबल, चेतावनियां और सावधानियां)
CYP3A Substrates Immunosuppressants that are CYP3A4 Substrates Mechanism and Clinical Effect(s) Posaconazole is a strong CYP3A4 inhibitor. (पोसाकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)
IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (प्रवास्टेटिन लेबल, चेतावनियां और सावधानियां)
In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (प्रोपाइलथायोयूरेसिल लेबल, चेतावनियां)
IMNM is characterized by proximal muscle weakness and elevated serum CK, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody, muscle biopsy showing necrotizing myopathy, and improvement with immunosuppressive agents. (फ्लुवास्टेटिन लेबल, चेतावनियां और सावधानियां)
- बुसल्फानमामूली
During the pregnancy that resulted in the malformed infant, the mother received x-ray therapy early in the first trimester, mercaptopurine until the third month, then busulfan until delivery. (बुसल्फान लेबल, चेतावनियां)
In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (मेथिमाज़ोल लेबल, चेतावनियां)
IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (रोसुवास्टेटिन लेबल, चेतावनियां और सावधानियां)
IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (लोवास्टेटिन लेबल, चेतावनियां)
IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (सिमवास्टेटिन लेबल, चेतावनियां और सावधानियां)
कोई महत्वपूर्ण इंटरैक्शन नहीं बताया गया (1)
…Repaglinide, Rosiglitazone: [See Warnings and Precautions ( 5.4 ) and Adverse Reactions ( 6.2 )] Insulin Insulin: [See Warnings and Precautions ( 5.4 ) and Adverse Reactions ( 6.2 )] Immunosuppressants: Cyclosporine Use With Caution Cyclosporine: There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with cyclosporine. (क्लैरिथ्रोमाइसिन लेबल, दवाओं के इंटरैक्शन)
आप जो कुछ भी लेते हैं, उस सबके साथ मर्कैप्टोप्यूरिन को जांचें। अपनी पूरी सूची जोड़ें; हर जोड़ी एक साथ जांची जाती है।
चेकर में खोलेंयह चिकित्सकीय सलाह नहीं है। गंभीरता लेबल के शब्दों को दर्शाती है, आपकी परिस्थितियों को नहीं। “गंभीर” चिह्न वाला संयोजन डॉक्टर की देखरेख में सामान्य बात हो सकता है, और “मामूली” चिह्न वाला संयोजन ऊंची खुराक पर मायने रख सकता है। फार्मासिस्ट से पूछें।